


AMENDMENTS

This listing of claims will replace all prior versions of claims in the application.

1-4. (Cancelled)

5. (Currently Amended) A 2-acylaminothiazole derivative represented by the following general Formula (V) or a pharmaceutically acceptable salt thereof:




wherein symbols have the following meanings:

Ar^2 : ~~a group represented by Ar^1 as described in claim 1, with the proviso that~~
indol-2-yl is excluded phenyl or monocyclic aromatic heterocycle, each of which may be
substituted (with the proviso that when R^3 is aryl or pyridyl, each of which may be
substituted with one or more groups selected from the group consisting of lower alkyl, -
CO-lower alkyl, -COO-lower alkyl, -OH, -O-lower alkyl, -OCO-lower alkyl, and halogen,
and R^4 is a group represented by the following general Formula (II); Ar^2 is not phenyl or
pyridyl, each of which may be substituted with one or more groups selected from the
group consisting of lower alkyl, -CO-lower alkyl, -COO-lower alkyl, -OH, -O-lower alkyl, -
OCO-lower alkyl, and halogen),

R^3 : ~~a group represented by R^1 as described in claim 1~~ aryl or monocyclic
aromatic heterocycle, each of which may be substituted,

R^4 : ~~a group represented by R^2 as described in claim 1, with the proviso that a~~

group represented by the general Formula (IV) is excluded a group represented by the following general formula (II) or (III):



wherein the symbols have the following meanings,

n: an integer of 1 to 3,

m: an integer of 1 to 3,

(when n or m is an integer of 2 or more, CR²⁰R²¹ and CR²²R²³ may be identical or different),

X: O, S, or a group represented by N-R²⁶ or C(-R²⁷)-R²⁸,

R²⁰, R²¹, R²², R²³, R²⁶, R²⁷, R²⁸, which may be identical or different, -H; -OH; -O-lower alkyl; optionally substituted lower alkyl; optionally substituted cycloalkyl; optionally substituted aryl; optionally substituted arylalkyl; optionally substituted aromatic heterocycle; optionally substituted aromatic heterocyclic alkyl; optionally substituted nonaromatic heterocycle; optionally substituted lower alkenyl; optionally substituted lower alkylidene; -COOH; -COO-lower alkyl; -COO-lower alkenyl; -COO-lower alkylene-aryl; -COO-lower alkylene-aromatic heterocycle; carbamoyl or amino, each of which may be substituted with one or more groups selected from the group consisting of lower alkyl and cycloalkyl, each of which may be substituted with halogen, -OH, -O-lower alkyl, or -O-aryl; -NHCO-lower alkyl; or oxo, and

R²⁴, R²⁵, which may be identical or different, -H, optionally substituted lower alkyl, optionally substituted cycloalkyl, or optionally substituted nonaromatic heterocycle.

6. (Cancelled)

7. (Currently Amended) The compound according to Claim-~~6~~ 5, wherein R³ is phenyl or thienyl, each of which may be substituted; R⁴ is a group represented by the general Formula (II); Ar² is phenyl or pyridyl, each of which may be substituted.

8. (Original) The compound according to claim 7, wherein n is 2, m is 2, and X is a group represented by N-R²⁶ or C(-R²⁷)-R²⁸.

9. (Currently Amended) The compound according to claim 8, wherein R³ is phenyl or thienyl, each of which may be substituted with 1 to 3 halogen atoms (when substituted with 2 or 3 halogen atoms, the halogen atoms may be identical or different[.]).

10. (Original) The compound according to claim 9, wherein R⁴ is 4-(piperidin-1-yl)piperidin-1-yl, 4-propylpiperidin-1-yl, 4-cyclohexylpiperazin-1-yl, or 4-propylpiperazin-1-yl.

11. (Original) The compound according to claim 10, wherein Ar² is phenyl which is unsubstituted at 2- and 6-positions, substituted with -H, -F, -Cl, or -Br at 3-position, substituted with -F, -Cl, or -Br at 5-position, and substituted at 4-position; or pyridin-3-yl which is unsubstituted at 2- and 4-positions, substituted with -F, -Cl, or -Br at 5-position, and substituted at 6-position.

12. (Currently Amended) The compound according to claim 11, wherein Ar² is phenyl which is substituted at 4-position with a group selected from the group consisting of -O-R^Y, -NH-R^Y, optionally substituted piperidin-1-yl and optionally substituted piperazin-1-yl; or pyridin-3-yl which is substituted at 6-position with a group selected from the group consisting of -O-R^Y, -NH-R^Y, optionally substituted piperidin-1-yl and optionally substituted piperazin-1-yl (wherein R^Y is lower alkyl which may be substituted with one or more groups selected from the group consisting of -OH, -O-lower alkyl, amino which may be substituted with one or two lower alkyl, -CO₂H, -CO-lower alkyl, carbamoyl which may be substituted with one or two lower alkyl, cyano, aryl, aromatic heterocycle, nonaromatic heterocycle and halogen[.]).

13. (Currently Amended) ~~A The compound according to any one of Claims 5 to 12,~~
~~wherein the compound is~~ selected from the group consisting of

N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide,

3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,

N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperidino)thiazol-2-yl]-2-methoxyisonicotinamide,

N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]isoquinoline-6-carboxamide,

3-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(3-hydroxypropoxy)nicotinamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-[(3-hydroxypropyl)amino]nicotinamide,

1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-cyanopiperidino)-3,5,-difluorobenzamide,

1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)thiazol-2-yl]-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidine-4-carboxylic acid,

1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)thiazol-2-yl]-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}-6-fluorophenyl)piperidin-4-carboxylic acid,

1-(2-chloro-4-{[4-(4-chlorothiophen-2-yl)thiazol-2-yl]-5-(4-propylpiperazin-1-yl)thiazol-2-yl]carbamoyl}phenyl)piperidin-4-carboxamide,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-(4-hydroxymethylpiperidino)nicotinamide,

1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

1-(3-chloro-5-{[5-(4-cyclohexylpiperazin-1-yl)-4-(3-trifluoromethylphenyl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-

{4-[(2-methoxyethyl)carbamoyl]piperidino}nicotinamide,
5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-
{4-[(3-methoxypropyl)carbamoyl]piperidino}nicotinamide,
5-chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-6-
[4-(morpholinocarbonyl)piperidino]nicotinamide, and
a pharmaceutically acceptable salt thereof.

14. (Currently Amended) A ~~pharmaceutical~~ composition comprising the compound of any one of Claims 5 or 7 to 13 as an active ingredient and a pharmaceutically acceptable carrier.

15-17. (Cancelled)